Literature DB >> 24216235

High-yield soluble expression of recombinant influenza virus antigens from Escherichia coli and their potential uses in diagnosis.

Yo Han Jang1, Seung Hee Cho1, Ahyun Son1, Yun Ha Lee1, Jinhee Lee1, Kwang-Hee Lee1, Baik Lin Seong2.   

Abstract

Although antiviral drugs and vaccines have been successful for mitigating influenza virus infections, the lack of general technical platform for the timely supply of soluble and highly purified influenza viral antigens presents a serious bottleneck for the subsequent analysis for the effective control of the viral disease. Using the Escherichia coli (E. coli) lysyl tRNA synthetase (LysRS) as a novel fusion partner, this study reports the soluble expression of influenza viral proteins in E. coli host, construction of antibody library against the virus, and detection of anti-influenza antibodies using the expressed viral antigens. When influenza A and B viral proteins were fused with the LysRS, the fusion proteins were expressed predominantly as soluble forms and their production yields were high enough to be amenable to immunization protocols in rabbits for antibody generation. The produced antibodies showed high level binding specificity against the respective viral proteins, with cross-reactivity across heterologous viruses within the same type of influenza viruses. In addition, LysRS-HA fusion protein could bind specifically to anti-HA antibodies in the virus-infected mouse serum in widely accepted two detection methods, Western blot and ELISA. These results present a convenient tool for the production of antibodies specific to the virus as well as the rapid detection of influenza viral infections, ultimately contributing to the control of influenza viruses including highly pathogenic H5N1, pandemic H1N1, or the recent H7N9 influenza viruses.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antibody library; Bacteria; ELISA; Fusion partner; Influenza viruses; Recombinant proteins

Mesh:

Substances:

Year:  2013        PMID: 24216235     DOI: 10.1016/j.jviromet.2013.10.035

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  7 in total

1.  Pan-Influenza A Protection by Prime-Boost Vaccination with Cold-Adapted Live-Attenuated Influenza Vaccine in a Mouse Model.

Authors:  Yo Han Jang; Joo Young Kim; Young Ho Byun; Ahyun Son; Jeong-Yoon Lee; Yoon Jae Lee; Jun Chang; Baik Lin Seong
Journal:  Front Immunol       Date:  2018-02-01       Impact factor: 7.561

2.  Green Tea Catechin-Inactivated Viral Vaccine Platform.

Authors:  Yun H Lee; Yo H Jang; Young H Byun; Yucheol Cheong; Paul Kim; Young J Lee; Yoon J Lee; Je M Sung; Ahyun Son; Hye M Lee; Jinhee Lee; Seung W Yang; Jae-Min Song; Baik L Seong
Journal:  Front Microbiol       Date:  2017-12-12       Impact factor: 5.640

3.  Harnessing an RNA-mediated chaperone for the assembly of influenza hemagglutinin in an immunologically relevant conformation.

Authors:  Seung Won Yang; Yo Han Jang; Soon Bin Kwon; Yoon Jae Lee; Wonil Chae; Young Ho Byun; Paul Kim; Chan Park; Young Jae Lee; Choon Kang Kim; Young Seok Kim; Seong Il Choi; Baik Lin Seong
Journal:  FASEB J       Date:  2018-01-02       Impact factor: 5.191

4.  Eliciting unnatural immune responses by activating cryptic epitopes in viral antigens.

Authors:  Young Jae Lee; Ji Eun Yu; Paul Kim; Jeong-Yoon Lee; Yu Cheol Cheong; Yoon Jae Lee; Jun Chang; Baik Lin Seong
Journal:  FASEB J       Date:  2018-03-23       Impact factor: 5.191

5.  Conversion of a soluble protein into a potent chaperone in vivo.

Authors:  Soon Bin Kwon; Kisun Ryu; Ahyun Son; Hotcherl Jeong; Keo-Heun Lim; Kyun-Hwan Kim; Baik L Seong; Seong Il Choi
Journal:  Sci Rep       Date:  2019-02-25       Impact factor: 4.379

6.  Epigallocatechin-3-Gallate as a Novel Vaccine Adjuvant.

Authors:  Yucheol Cheong; Minjin Kim; Jina Ahn; Hana Oh; Jongkwan Lim; Wonil Chae; Seung Won Yang; Min Seok Kim; Ji Eun Yu; Sanguine Byun; Yo Han Jang; Baik Lin Seong
Journal:  Front Immunol       Date:  2021-11-12       Impact factor: 7.561

Review 7.  Options and obstacles for designing a universal influenza vaccine.

Authors:  Yo Han Jang; Baik Lin Seong
Journal:  Viruses       Date:  2014-08-18       Impact factor: 5.048

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.